This is a correction to: Inga Dunsche, Ellen L Raddatz, Haide Ismer, Silke Hedtfeld, Stephanie Tamm, Saskia Moser, Julia Kontsendorn, Burkhard Tümmler, Sabina Janciauskiene, Anna-Maria Dittrich, Frauke Stanke, Analysis of CF patient survival confirms STAT3 as a CF-modifying gene with changing impact over time, Human Molecular Genetics, 2022, ddac221, https://doi.org/10.1093/hmg/ddac221
In the originally published version of this manuscript, Table 1 had two columns incorrectly transposed. The information under “Patients' genotype at STAT3: both STAT3Sat alleles =16 ARU” “No of patients, n (%)”, should be swapped with that under “Patients' genotype at STAT3: both STAT3Sat alleles =12 ARU” “No of patients, n (%)”.
This error has been corrected online.
Table 1.
Patient survival by STAT3Sat genotype
| Year of birth | No of patients | Patients’ genotype at STAT3: both STAT3Sat alleles ≥16 ARU | Patients genotype at STAT3: both STAT3Sat alleles ≤12 ARU | Patient is heterozygous at STAT3Sat | P | |||
|---|---|---|---|---|---|---|---|---|
| No of patients, n (%) | Median survival | No of patients, n (%) | Median survival | No of patients, n (%) | Median survival | |||
| 1959–1994 | 165a | 15 (8.6%) | n.d. | 66 (37.9%) | n.d. | 84 (48.3%) | n.d. | n.d. |
| 1959–1976 | 78 | 7 (8.8%) | 30 years | 26 (32.5%) | ≈50 years | 45 (56.3%) | 35 years | 0.023 |
| 1972–1983 | 75 | 9 (11.3%) | 42 years | 27 (33.8%) | 36 years | 39 (48.8%) | 35 years | 0.406 |
| 1977–1994 | 75 | 7 (8.8%) | 36 years | 35 (43.8%) | 32 years | 33 (41.3%) | 37 years | 0.913 |
aOut of 174 p.Phe508del-CFTR homozygotes, the STAT3Sat genotype could not be resolved for eight patients. One patient carried SAT3Sat-14 on both chromosomes and thus could not be classified in either group ‘carries at least one allele STAT3Sat-16 or more ARU’ or ‘both alleles STAT3Sat-12 or less ARU’.